COPD is a progressive disease where airway inflammation plays an important part. Previously, there were large expectations that regular anti-inflammatory treatment with inhaled corticosteroids (ICS) ...

The FDA recently approved mepolizumab for treating adults with inadequately controlled COPD and an eosinophilic phenotype, marking the second biologic approved as an add-on maintenance treatment ...

Women aged 40 years and older have a 50% greater risk for chronic obstructive pulmonary disease (COPD) vs men in the same age group, according to study findings published in BMJ Open Respiratory ...

In smokers with COPD, LABA+LAMA is more effective than LABA+ICS in preventing exacerbations, regardless of blood eosinophil count.

Antibiotic demand for pneumonia and COPD in the top 20 countries showed high global consumption.

Introduction In patients with chronic obstructive pulmonary disease (COPD), the risk of certain cardiovascular (CV) events is increased by threefold to fivefold in the year following acute ...

Tezepelumab has received an FDA breakthrough therapy designation as a maintenance treatment for patients with moderate to very severe COPD characterized by an eosinophilic phenotype, according to ...

Home-based pulmonary rehabilitation has been slowly gaining momentum for chronic obstructive pulmonary disease (COPD), but access is still a challenge.

Background Oscillatory positive expiratory pressure (OPEP) devices are intended to facilitate sputum clearance and reduce cough, but there is limited evidence for their effectiveness in COPD, or to ...